EBS

Emergent BioSolutions Inc. · NYSE · Healthcare · USD · 10-K for 2025, filed 2026-02-27

Figures on this page computed 2026-11-08 12:12 UTC

Last close

5.90USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-27

6.2xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-27
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-11-03
The filing itself
7.1%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
21.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-11-03
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.32 against 0.47 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.73x

-1.58x

3.28x

0.81x

0.17x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-27

Sales0.73x
Its own average over 10 years, 1.02B.
Profit-1.58x
Its own average over 10 years, -33.3M.
Free cash flow3.28x
Its own average over 10 years, 47.8M.
Debt0.81x
Its own average over 10 years, 723.6M.
Price0.17x
Its own average over 11 years, 36. Market data, 2026-11-04

Profit is furthest from its own average, at -1.58 times.

Sales is 0.73 times its own 10-year average; Profit is -1.58 times its own 10-year average; Free cash flow is 3.28 times its own 10-year average; Debt is 0.81 times its own 10-year average; Price is 0.17 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-27

Sales against its own 10-year average0.73
Source
filed
Statement
income
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
The filing itself
Profit against its own 10-year average-1.58
Source
filed
Statement
income
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
The filing itself
Free cash flow against its own 10-year average3.28
Source
filed
Statement
income
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
The filing itself
Debt against its own 10-year average0.81
Source
filed
Statement
income
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
The filing itself
Price against its own 11-year average0.17Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD